Dacomitinib as a First‐Line Therapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study

ABSTRACT Background Real‐world evidence regarding the use of dacomitinib as a first‐line therapy for advanced non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations remains limited. This multicenter, retrospective cohort study aimed to evaluate the clinical outcome...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Ping‐Chih Hsu, How‐Wen Ko, Li‐Chung Chiu, Shih‐Hao Huang, Chung‐Shu Lee, Yu‐Ching Lin, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Chin‐Chou Wang, Cheng‐Ta Yang
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2026-03-01
Saila:	Cancer Medicine
Gaiak:	common EGFR mutation dacomitinib epidermal growth factor receptor mutation non‐small cell lung cancer (NSCLC) tyrosine kinase inhibitor
Sarrera elektronikoa:	https://doi.org/10.1002/cam4.71659
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!